GlobeNewswire: Ablynx Contains the last 10 of 139 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:57:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/10/20/880958/10165709/en/ABLYNX-OUTLINES-NEXT-STEPS-FOR-ITS-ANTI-IL-6R-NANOBODY-VOBARILIZUMAB-A-POTENTIAL-BEST-IN-CLASS-TREATMENT-FOR-RHEUMATOID-ARTHRITIS.html?f=22&fvtc=4&fvtv=20143ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS2016-10-20T05:05:56Z<![CDATA[Webcast presentation, including additional results from the Phase IIb RA studies of vobarilizumab, will take place today at 4pm CET/10am EST (details below) - slides available on the Ablynx website
( R&D portfolio )]]>https://www.globenewswire.com/news-release/2016/10/12/878761/10165570/en/ABLYNX-ANNOUNCES-SECOND-EXTENSION-OF-ITS-ION-CHANNEL-RESEARCH-COLLABORATION-WITH-MERCK-CO-INC.html?f=22&fvtc=4&fvtv=20143ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.2016-10-12T05:04:27Z<![CDATA[GHENT, Belgium, Oct. 12, 2016 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2016/10/11/878376/10165549/en/FMR-LLC-ANNOUNCE-9-22-SHAREHOLDING-IN-ABLYNX.html?f=22&fvtc=4&fvtv=20143FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX2016-10-11T05:05:20Z<![CDATA[REGULATED INFORMATION]]>https://www.globenewswire.com/news-release/2016/10/10/878084/10165526/en/ABLYNX-INITIATES-A-PHASE-III-FOLLOW-UP-STUDY-OF-ITS-FIRST-IN-CLASS-WHOLLY-OWNED-ANTI-vWF-NANOBODY-CAPLACIZUMAB-FOR-THE-TREATMENT-OF-ACQUIRED-TTP.html?f=22&fvtc=4&fvtv=20143ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP2016-10-10T05:15:40Z<![CDATA[
GHENT, Belgium, Oct. 10, 2016 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2016/09/29/875478/10165362/en/ABLYNX-S-FIRST-IN-CLASS-WHOLLY-OWNED-ANTI-vWF-NANOBODY-CAPLACIZUMAB-MAY-HAVE-THE-POTENTIAL-TO-REDUCE-MORBIDITY-AND-MORTALITY-ASSOCIATED-WITH-ACQUIRED-TTP.html?f=22&fvtc=4&fvtv=20143ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP 2016-09-29T05:05:23Z<![CDATA[Additional data from post-hoc analyses of the Phase II TITAN study to be presented at the European Congress on Thrombosis and Haemostasis (ECTH) GHENT, Belgium, Sept. 29, 2016 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2016/09/15/871969/10165114/en/ABLYNX-RECEIVES-TRANSPARENCY-NOTIFICATION-FROM-OPPENHEIMER-FUNDS-INC.html?f=22&fvtc=4&fvtv=20143ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.2016-09-15T05:07:58Z<![CDATA[REGULATED INFORMATION]]>https://www.globenewswire.com/news-release/2016/09/06/869492/10164967/en/Ablynx-Receives-Transparency-Notification-From-GAM-Holding-AG-GAM-International-Management-Limited-and-Taube-Hodson-Stonex-Partners-LLP.html?f=22&fvtc=4&fvtv=20143Ablynx Receives Transparency Notification From GAM Holding AG, GAM International Management Limited and Taube Hodson Stonex Partners LLP2016-09-06T05:19:47Z<![CDATA[
GHENT, Belgium, Sept. 6, 2016 (GLOBE NEWSWIRE) --]]>https://www.globenewswire.com/news-release/2016/08/25/866728/10164801/en/ABLYNX-ANNOUNCES-2016-HALF-YEAR-RESULTS-AND-YEAR-TO-DATE-BUSINESS-UPDATE.html?f=22&fvtc=4&fvtv=20143ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE2016-08-25T05:10:02Z<![CDATA[REGULATED INFORMATION]]>https://www.globenewswire.com/news-release/2016/08/17/864678/10164593/en/ABLYNX-WILL-ANNOUNCE-ITS-2016-HALF-YEAR-RESULTS-WITH-WEBCAST-ON-25-AUGUST-2016.html?f=22&fvtc=4&fvtv=20143ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 20162016-08-17T05:09:31Z<![CDATA[GHENT, Belgium, Aug. 17, 2016 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2016/08/12/863759/10164540/en/ABLYNX-RECEIVES-TRANSPARENCY-NOTIFICATION-FROM-ADRIANUS-VAN-HERK-ANDVAN-HERK-INVESTMENTS-B-V.html?f=22&fvtc=4&fvtv=20143ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.2016-08-12T05:06:39Z<![CDATA[REGULATED INFORMATION]]>